Analytical Data
-
Gene name
ancrod
- Application
-
Alternative Names
; Thrombin-like enzyme ancrod; SVTLE; EC 3.4.21.74; Fibrinogen-clotting enzyme; Snake venom serine protease; SVSP; Venombin A
-
Species
Calloselasma rhodostoma
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P26324
-
Expression Region
1-234aa
-
Molecular Weight
28.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Ancrod, a Fredrickson and Sweeney-derived snake venom enzyme, has garnered attention in the field of biopharmaceutical research due to its unique mechanism of action as a defibrinating agent. This serine protease, originally extracted from the venom of the Malayan pit viper, is known for its ability to selectively cleave fibrinogen, resulting in the formation of fibrin degradation products and subsequent reduction of blood viscosity. The application of ancrod has been explored for various medical conditions, particularly in treating thrombotic disorders such as ischemic stroke and peripheral artery disease, as it offers a potentially safer alternative to traditional anticoagulants. Furthermore, its action on the coagulation pathways has led researchers to investigate its therapeutic potential in enhancing microcirculation and promoting tissue perfusion in ischemic tissues. Advances in recombinant DNA technology have enabled the production of recombinant ancrod proteins, which promise improved safety profiles and pharmacological properties. This research is pivotal, as it not only aims to optimize ancrod for clinical use but also enhances our understanding of coagulation mechanisms and their implications in various disease states. Overall, the study of recombinant ancrod serves as a significant contribution to the development of novel therapies that may mitigate the risks associated with thrombotic events while providing insights into targeted drug design.
